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Background. There has been an increase in antimicrobial resistance among GN
pathogens, not only in adults, but also pediatrics. UTIs are common in pediatrics; however, reports of pediatric UTI with ESBL producing GN are limited.
Methods. All urine cultures positive for ESBL producing GN from 5/1/18 to
December 31/18 were retrospectively reviewed. Proven infection (PI) defined as
≥50,000 colony-forming units (CFU)/mL of bacteria plus pyuria or positive leukocyte esterase for catheterized or clean catch specimens. Relapsed infection defined as
same pathogen cultured within 30 days of infection. Abnormal urinary tract systems
or functions (AUTS) include neurogenic bladder, structural anomalies, or intermittent
catheterization.
Results.
A total of 107 urine cultures for ESBL producing GN, from 85
patients, were included. Majority of specimens [78/107 (73%)] were obtained from
the ED or outpatient clinics. 43% of specimens were from patients with AUTS.
E. coli was the majority (95%) of ESBL isolates. 57% of ESBL producing GNs were
susceptible to amoxicillin/clavulanate (AC) or trimethoprim/sulfamethoxazole
(TMP/SMX). 88% were nitrofurantoin susceptible. Only 1 isolate was meropenem
resistant. Antibiotics (ABX) were prescribed for UTI in 67/107 episodes. However,
only 52 episodes were PI. Of these, 38 were empirically treated with oral ABX and
29 with intravenous ABX. The most commonly prescribed empiric ABX was oral
cephalexin (25/67, 37%.) Ineffective empiric ABX for UTI was very common, 83%
(43/52). Of these, 5/43 never received effective therapy and none had relapse. Most
common duration of ABX was 10 days (range 5–17 days.) 43% (23/52) of PI were
treated with oral AC or TMP/SMX. 15% (8/52) of PI were treated with nitrofurantoin. 12% of PI were treated with a once-daily aminoglycoside. Only 6% of PI were
treated with a carbapenem.
Conclusion. Many ESBL UTI isolates remain susceptible to oral ABX. Although
small numbers, patients treated with ineffective ABX did not return with relapsed
infection. Non-carbapenem ABX are a reasonable option to minimize selective pressure or unnecessary use. Empiric narrow-spectrum antibiotic therapy may still be
appropriate.
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Background. Infections with extended-spectrum β-lactamase (ESBL) producing Enterobacteriaceae is an emerging problem leading to poor clinical outcomes and
increased mortality. The purpose of this study was to determine the prevalence, risk
factors and outcomes of ESBL-producing E. coli (EC) in bloodstream infections (BSIs)
of neutropenic patients with hematological malignancies and compare the difference
with Non-ESBL producing EC.
Methods. Through an IRB approved protocol, a retrospective cohort study was
conducted at the H. Lee Moffitt Cancer Center from January, 2007 till October, 2017.
Of the 310 records, who had +ive blood cultures for E. Coli, a total of 63 neutropenic
patients with hematological malignancies were identified based on the bloodstream
infections with ESBL-EC and Non ESBL EC. Data included demographics, underlying
malignancy, type of bone marrow transplant, duration of neutropenia, antibiotics use
pre and post culture, length of hospital stay, severity of infection, ventilator use, and
mortality data.
Results. A total of 310 cases with hematological malignancy and neutropenia were reviewed, 63 were identified as +ive blood culture for E. coli. Out of
the 63 cases, 17 were ESBL-EC +ive and 46 were non-ESBL-EC. The prevalence of
ESBL-EC was highest in the year 2015 (29.4%) and decreased in the subsequent
years (Figure 1). The mean ages of the two groups were 53.59 ±12.4 and 60.82 ±
11.1, respectively. The average length of stay for the ESBL-EC group was 26.59 ±
11.2 days, longer than the non-ESBL EC group 21.96 ± 11.2. Days of neutropenia
in non-ESBL vs. ESBL EC were 9 days ± 8.3, and 19 days ± 22.0, respectively, P
< 0.01). No differences were observed in the 30–60 day mortality and other outcomes listed in Table 1.
Conclusion. The prevalence of ESBL-EC was observed to be higher in patients
who were neutropenic for longer duration, were older and resulted in longer hospital
stay. Early identification and empirical therapy in neutropenic patients suspected to
have ESBL-EC infection is crucial. Also, the infection with ESBL-EC was higher in the
year 2015 and decreased in the subsequent years. After higher rates, perhaps infection
control, lab reporting changes, antibiotic stewardship and transmission-based precautions might have played a role.
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Results. Of 408 patient of community-onset KP BSI, 70 (17%) were ESBL-KP BSI
patients. ESBL-KP isolates most frequently carried CTX-M-1-group ESBLs (74%, n =
52), followed by CTX-M-9-group ESBLs (16%, n = 11). Most prevalent sequence type
(ST) among ESBL-KP isolates was ST48 (14%, n = 10). Among non-ESBL-KP isolates,
ST23 was most prevalent (21%, n = 70). Analyzing with multivariate analysis, recent
admission to long-term care hospital within 3 months (OR, 5.7; 95% CI, 2.1–15.6; P =
0.001), previous usage of trimethoprim-sulfamethoxazole (OR, 11.5; 95% CI, 2.7–48.6;
P = 0.001), expanded-spectrum cephalosporin (OR, 2.2; 95% CI, 1.2–3.9; P = 0.01),
and previous use of urinary catheter (OR, 2.3; 95% CI, 1.1–4.5; P = 0.02) were identified as independent risk factors for community-onset ESBL-KP BSI.
Conclusion. Recent admission to long-term care hospital, use of urinary catheter, recent usage of antibiotics were identified as risk factors for community-onset ESBL-KP BSI. Strict antibiotic stewardship and infection control measures in
long-term care hospital are needed.
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Background. Cancer patients are susceptible to infections due to immunodeficiency, frequent invasive interventions-devices, chemotherapy and antibiotics
exposure. Infections caused by extended-spectrum β-lactamase (ESBL)-producing
Enterobacteriaceae increase morbidity and mortality. The objective was to identify
clinical factors associated with ESBL in infected patients with cancer at the Instituto
Nacional de Cancerología.
Methods. A case–control study was conducted from 2013 to 2015. Cases were
infected patients with ESBL-producer Enterobacteriaceae. Controls (matched for date
and ward) with non-ESBL-producer Enterobacteriaceae were included. Data were
extracted from electronic medical records at index culture: clinical and admission data,
Charlson index, immunosuppressive, radio and chemotherapy, neutropenia, invasive
devices, surgical procedures and antimicrobial therapy. Microorganisms were identified by the automatized system. Conditional logistic regression and backward stepwise
was used to identify predictors of ESBL isolation.
Results. A total of 265 patients with ESBL producer Enterobacteriaceae and
445 non-ESBL producers were identified, mean age 59, 61% male, 48% admitted
as outpatients, 73% with solid tumors, 38% with Charlson index ≥4. E.coli and
Klebsiella spp. represented 90% of microorganisms. Factor associated with ESBL
producer Enterobacteriaceae were hospitalization ≥7 days (OR: 1,59; CI 1.11–2,29),
hospitalization the previous year (OR: 4.02; CI 2,68–6,02), immunosuppressive
therapy (OR: 2.07; CI 1,05–4.05), Β-lactam therapy the last month (OR: 1.54; CI
1.05–2.26), invasive devices (OR: 1.58; CI 1.10–2.27), active neoplasia (OR: 2,22;
CI1.05–4.68), neutropenia (OR: 2.03; CI:1.26–3.27) and absence of chemotherapy
during last 3 months (OR: 1.91; CI1.29–2.82). Discriminatory capacity was acceptable (AUC: 0.71).
Conclusion. The presence of ESBL-producer Enterobacteriaceae in oncologic
patients is associated with health care, hospital admission and length of stay, invasive devices and exposure to antibiotics. The magnitude of associated factors are weak
and do not completely allow the identification of cancer patients infected with ESBLproducer Enterobacteriaceae.
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